
CohBar Investor Relations Material
Latest events

M&A Announcement
CohBar
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from CohBar Inc
Access all reports
CohBar Inc. is a clinical-stage biotechnology company focused on developing therapeutics based on peptides derived from mitochondrial DNA. The company’s research centers on leveraging its proprietary mitochondrial peptide technology platform to address chronic and age-related diseases. CohBar’s pipeline targets conditions such as metabolic disorders, fibrotic diseases, cancer, and neurodegenerative diseases. The company is headquartered in Menlo Park, California, and its shares are listed on the NASDAQ Stock Exchange.
Latest articles
)
Robert G. Hagstrom: Darwinian Investing and Multidisciplinary Wisdom
Robert G. Hagstrom, author of The Warren Buffett Way, explores how interdisciplinary thinking shapes his investing, from Adler's reading to Darwinian markets.
7 Feb 2025
)
Quartr Brings Stories Behind the Numbers to Light
Quartr simplifies access to IR material and puts qualitative insights and company narratives front and center.
3 Feb 2025
)
The Evolution of the IRO Role: Staying Informed and Strategic With Quartr Pro
Staying informed is critical for IROs. Quartr Pro simplifies gathering market insights and narrative positioning with unprecedented speed and precision.
3 Feb 2025
Ticker symbol
CWBR
Country
🇺🇸 United States